Related Experiment Video

Updated: May 16, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

New developments and future directions in systemic therapy

A Sheri1, S Johnston

  • 1Breast Unit, Royal Marsden Hospital, London, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|December 11, 2012
PubMed

Insights

Adjuvant systemic therapies improve breast cancer survival, but many patients still relapse. Research is ongoing to understand resistance and identify new biomarkers for effective treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Translational Research

Background:

  • Adjuvant systemic therapies significantly reduce breast cancer relapse and improve survival.
  • A considerable number of breast cancer patients still develop metastatic disease despite treatment.

Purpose of the Study:

  • To review recent advancements in systemic therapies for breast cancer.
  • To discuss challenges in translational research, including resistance mechanisms and novel therapy effectiveness.
  • To highlight key findings from novel agent trials and the need for response biomarkers.

Main Methods:

  • Review of recent clinical trials for breast cancer systemic therapies.
  • Analysis of endocrine therapy, chemotherapy, and targeted therapy advancements.
  • Identification of resistance drivers and compensatory mechanisms impacting novel therapies.

Main Results:

  • Progress in systemic therapies has improved outcomes but not eliminated relapse.
  • Identifying resistance mechanisms is crucial for developing more effective treatments.
  • Not all novel targeted agents demonstrate sufficient efficacy for approval.

Conclusions:

  • Further research is essential to overcome treatment resistance in breast cancer.
  • Biomarker identification is critical for predicting response to systemic therapies.
  • Translational research must focus on understanding and targeting resistance pathways.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...